Molecular phenotypes of colorectal cancer and potential clinical applications
Open Access
- 3 September 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 3 (4) , gov046-276
Abstract
Colorectal cancer (CRC) is a heterogeneous disease, arising from many possible etiological pathways. This heterogeneity can have important implications for CRC prognosis and clinical management. Epidemiological studies of CRC risk and prognosis—as well as clinical trials for the treatment of CRC—must therefore be sensitive to the molecular phenotype of colorectal tumors in patients under study. In this review, we describe four tumor markers that have been widely studied as reflections of CRC heterogeneity: (i) microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency, (ii) the CpG island methylator phenotype (CIMP), and somatic mutations in (iii) BRAF and (iv) KRAS. These tumor markers have been used to better characterize CRC epidemiology and, increasingly, may be used to guide clinical decision-making. Going beyond these traditional tumor markers, we also briefly review some more novel markers likely to be of clinical significance. Lastly, recognizing that none of these individual tumor markers are isolated attributes but, rather, a reflection of broader tumor phenotypes, we review some of the hypothesized etiological pathways of CRC development and their associated clinical differences.Keywords
This publication has 125 references indexed in Scilit:
- Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancersThe Journal of Pathology, 2013
- Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancerInternational Journal of Cancer, 2012
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon CancerJAMA, 2012
- The CpG island methylator phenotype in colorectal cancer: Progress and problemsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancerBritish Journal of Surgery, 2009
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: Results from the Netherlands Cohort StudyMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- CpG Islands in vertebrate genomesJournal of Molecular Biology, 1987